Extreme-hypofractionated RT with concomitant boost to the DIL in PCa: a 5-year update on oncological and patient-reported outcomes for the phase II trial "GIVE ME FIVE".

Giulia MarvasoGiulia CorraoIlaria RepettiChiara LorubbioFederica BellerbaMattia ZaffaroniMaria Giulia VinciniDario ZeriniSarah AlessiStefano LuzzagoFrancesco Alessandro MistrettaCristiana FodorRaffaella CambriaFederica CattaniFrancesco CeciGennaro MusiOttavio De CobelliThomas ZilliSara GandiniRoberto OrecchiaGiuseppe PetraliaBarbara Alicja Jereczek-Fossa

Published in: World journal of urology (2024)

The study confirms that extreme hypofractionation with a DIL boost is safe and effective, with no severe effects on the QoL. The increasing dose to the DIL does not worsen the RT toxicity, thus opening the possibility of an even more escalated treatment.

Keyphrases

patient reported outcomes
climate change
radiation therapy
rectal cancer
open label
randomized controlled trial
clinical trial
drug induced